INTRODUCTION AND AIMS:
Although the administration of antiplatelet and/or anticoagulant drugs has not been discontinued before arteriovenous fistula (AVF) or arteriovenous graft (AVG) surgery, its use has not been generally unified. The aim of this study was to examine the effect of these drugs on postoperative bleeding. METHODS: We performed a single-centre retrospective cohort study involving 329 patients who underwent AVF or AVG surgery at our centre between September 2014 and October 2017. We classified the patients into two groups as those taking antiplatelet and/or anticoagulant drugs and those not taking them. The outcome was bleeding that required reoperation within 2 weeks postoperatively. RESULTS: In total, 137 patients took antiplatelet and/or anticoagulant drugs and 192 did not. There was no significant difference between this two groups [0 vs 1; p ¼ 0.39]. There was also no significant difference in the occurrence of vascular access obstruction within 2 weeks postoperatively [0 vs 1; p ¼ 0.23]. CONCLUSIONS: Taking antiplatelet and/or anticoagulant drugs did not cause postoperative bleeding that required reoperation; therefore, it is not necessary to stop oral antiplatelet and/or anticoagulant drug administration before AVF or AVG surgery.
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INTRODUCTION AND AIMS:
We studied the relation of local and systemic complications with time of creation of AVF in regard of beginning of HD. METHODS: There are more than 2,300 patients under observation in the Moscow regional centre who get HD in 41 dialysis centres. Our analysis includes 1862 patients from register of HD patient. The median follow-up was 48 [32; 52] months.
RESULTS:
The proportion of vascular access types was significantly influenced by the causes of CKD. Term of AVF creation was ranging widely from 1 to 509 days before the HD, however, the median was 38 [IQR 15; 89] In most cases this is due to the hypotension. Thus, in case of unscheduled start of HD it is better to postpone the creation of AVF. Systemic complications. In the total cohort of patients in our study, the initiation of HD with CVC reduced the survival rate (log rank p<0.001). However, after adjustment for other risk factors (the most important of which was the comorbidity), we did not observe differences in survival rate between patients who started HD through the AVF and the CVC, provided successful conversion to AVF (log rank p¼0.323). This coincides with the results of other authors.In spite of this, in the overall cohort the IRR of infections in case of using CVC 7.6 times higher [95%CI 5.2; 10.7] compared to AVF/AVG, IRR of dysfunction -4.1 [95% CI 2.5; 5.1]. In patients group with adverse cardiovascular background, the creation of AVF prior 9 and more months before initiation of HD is associated with an increased risk of cardiovascular events and death (IRR 1.532, 95% CI 1.129; 1.848, p¼0.001), compared with the later AVF creation. The question of the optimal time of AVF creation in this subgroup requires a further study.In multivariate Poisson regression model, an important risk factor for death was the cause of CKD -diabetes mellitus and "system processes" (vasculitis, multiple myeloma, cancer, HIV and chemotherapy or narcomania in anamnesis). The use of the CVC in patients with diabetes even with subsequent successful conversion to AVF significantly increases mortality (incidence rate ratio ( 
